TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy

Table 2

Multivariate model of baseline demographic and clinical variables as predictors of response to anti-TNF treatment at 6 months.

Baseline variables	Coefficient ( value)
Age (years)	−0.01 (0.25)
Disease duration (years)	0.01 (0.24)
Female gender	−0.01 (0.95)
ACPA (positive)	−0.07 (0.64)
Smoking (ever)	−0.06 (0.72)
Higher education (years)	0.03 (0.03)^*
Corticosteroids (yes)	−0.16 (0.26)
DMARDs (yes)	0.05 (0.83)
Extra-artic. manif. (yes)	0.10 (0.49)
HAQ	−0.40 (0.002)^*
PhGA (mm)	−0.001 (0.68)
DAS	0.60 (<0.001)^*

value <0.05.
The probability of response to anti-tumor necrosis factor therapy at 6 months was modeled in a multivariate linear regression analysis.
The change in disease activity score assessing 28 joints between the baseline visit and the visit after 6 months of therapy was the continuous outcome.
ACPA: anticitrullinated peptides antibodies; DMARDs: disease modifying antirheumatic drugs; Extra-artic. manif.: extra-articular manifestations; HAQ: Health Assessment Questionnaire; PhGA: physician global assessment; DAS: disease activity score.